Vertex Pharmaceuticals (VRTX)
NASDAQ: VRTX · Biotechnology · Boston, MA
Our rating: Positive
Positive reaffirmed at $549.04, moderate conviction, November 4, 2026.
Breaks if: The Positive call is undermined if revenue growth in two consecutive quarterly filings over the next twelve months decelerates below 5% — at that rate the 35.8x earnings multiple loses its anchor and the view tips toward Neutral or Cautious. The call would need to escalate to Conviction if free cash flow closes to within $300M of net income across two straight quarterly filings while a second material revenue stream appears at reportable scale in the company's disclosures.
Key figures
| Market value | $130.6B |
|---|---|
| Revenue, last 12 months | $13.0B |
| Net income, last 12 months | $4.0B |
| Free cash flow, last 12 months | $3.2B |
| Price to earnings | 32.8× |
| Free cash flow yield | 2.5% |
| Dividend yield | 0.0% |
| Operating margin | 33.2% |
| Return on equity | 20.8% |
| Beta to the S&P 500 | 0.46 |
| Volatility, annualized | 30.8% |
Reported quarters
| Quarter ending | Revenue | Year on year | Earnings per share | Free cash flow |
|---|---|---|---|---|
| September 30, 2026 | $3.4B | 11.8% | $2.56 | $546M |
| June 30, 2026 | $3.3B | 12.5% | $4.31 | $1.0B |
| March 31, 2026 | $3.0B | 7.8% | $4.02 | $1.3B |
| December 31, 2025 | $3.2B | 9.5% | $4.64 | $349M |
| September 30, 2025 | $3.1B | 11.0% | $4.20 | $1.1B |
| June 30, 2025 | $3.0B | 12.1% | $3.99 | $927M |
| March 31, 2025 | $2.8B | 3.0% | $2.49 | $778M |
| December 31, 2024 | $2.9B | 15.7% | $3.53 | $492M |
Three-model forecasts for the next quarter
Written November 21, 2026, before the report. Each settles from the SEC filing.
- Revenue for the quarter is at least $3.52B: Claude 60%, Gemini 90%, Mistral 75%
- Diluted earnings per share are at least $4.64: Claude 38%, Gemini 20%, Mistral 40%
- Free cash flow for the quarter is at least $0.35B: Claude 65%, Gemini 90%, Mistral 85%
13 ledger entries and 15 corporate events on record. Share price as of November 20, 2026. Research and education only. Not investment advice. Stoquity does not manage money or know your circumstances. Ratings, forecasts and lists are produced by software and AI models and can be wrong. Performance figures are hypothetical, measured on paper against a benchmark, and say nothing certain about the future.